| abstract |
Compounds of formula (I) wherein: R represents a substituent selected from: a hydrogen or a substituent as defined in the claims; R2 represents a hydrogen atom or a C¿1-4?alkyl group; q is 1 or 2; A represents a group of formula (a), (b) or (c) wherein: Ar represents an optionally substituted phenyl ring or an optionally substituted 5- or 6-membered aromatic heterocyclic ring; or an optionally substituted bicyclic ring system; Ar?1 and Ar2¿ each independently represent an optionally substituted phenyl ring or an optionally substituted 5- or 6-membered aromatic heterocyclic ring; and Y represents a bond, -NHCO-, -CONH-, -CH¿2?-, or -(CH2)mY?1(CH¿2)n-, wherein Y1 represents O, S, SO¿2?, or CO and m and n each represent zero or 1 such that the sum of m+n is zero or 1; providing that when A represents a group of formula (a), any substituent present in Ar ortho to the carboxamide moiety is necessarily a hydrogen or a methoxy group; and salts thereof. Compounds of formula (I) and their salts have affinity for dopamine receptors, in particular the D3 receptor, and thus potential in the treatment of conditions wherein modulation of the D3 receptor is beneficial, e.g. as antipsychotic agents. |